Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech

The spike-protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has developed different adverse reactions. Still, delirium has not been reported in a low-risk patient, and it is important to consider it and recognize it as a possibility in all severity risk patients. We presen...

Full description

Saved in:
Bibliographic Details
Main Authors: Lilia M. Sierra Galan, Raquel Cohen Shaooli
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-01-01
Series:APIK Journal of Internal Medicine
Subjects:
Online Access:https://journals.lww.com/10.4103/ajim.ajim_66_21
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841556583071350784
author Lilia M. Sierra Galan
Raquel Cohen Shaooli
author_facet Lilia M. Sierra Galan
Raquel Cohen Shaooli
author_sort Lilia M. Sierra Galan
collection DOAJ
description The spike-protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has developed different adverse reactions. Still, delirium has not been reported in a low-risk patient, and it is important to consider it and recognize it as a possibility in all severity risk patients. We present a 76-year-old male patient who developed delirium after receiving the second dose of the BNT162b2 mRNA vaccine from Pfizer Inc. and BioNTech®. We theorize about the potential pathophysiology mechanisms involved.
format Article
id doaj-art-888cf94921664aca997b63b256dc34c9
institution Kabale University
issn 2666-1802
2666-1810
language English
publishDate 2025-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series APIK Journal of Internal Medicine
spelling doaj-art-888cf94921664aca997b63b256dc34c92025-01-07T07:14:00ZengWolters Kluwer Medknow PublicationsAPIK Journal of Internal Medicine2666-18022666-18102025-01-01131757710.4103/ajim.ajim_66_21Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTechLilia M. Sierra GalanRaquel Cohen ShaooliThe spike-protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has developed different adverse reactions. Still, delirium has not been reported in a low-risk patient, and it is important to consider it and recognize it as a possibility in all severity risk patients. We present a 76-year-old male patient who developed delirium after receiving the second dose of the BNT162b2 mRNA vaccine from Pfizer Inc. and BioNTech®. We theorize about the potential pathophysiology mechanisms involved.https://journals.lww.com/10.4103/ajim.ajim_66_21adverse reactiondeliriuminterleukinlow-risk patientspike-protein severe acute respiratory syndrome coronavirus 2 vaccine
spellingShingle Lilia M. Sierra Galan
Raquel Cohen Shaooli
Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
APIK Journal of Internal Medicine
adverse reaction
delirium
interleukin
low-risk patient
spike-protein severe acute respiratory syndrome coronavirus 2 vaccine
title Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
title_full Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
title_fullStr Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
title_full_unstemmed Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
title_short Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
title_sort delirium as an adverse reaction to bnt162b2 mrna vaccine from pfizer inc and biontech
topic adverse reaction
delirium
interleukin
low-risk patient
spike-protein severe acute respiratory syndrome coronavirus 2 vaccine
url https://journals.lww.com/10.4103/ajim.ajim_66_21
work_keys_str_mv AT liliamsierragalan deliriumasanadversereactiontobnt162b2mrnavaccinefrompfizerincandbiontech
AT raquelcohenshaooli deliriumasanadversereactiontobnt162b2mrnavaccinefrompfizerincandbiontech